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Abstract
Cardiovascular (CV) disease and osteoporosis (OP) have become increasing challenges in the aging population and
even more in patients with inflammatory rheumatic diseases, such as rheumatoid arthritis, spondyloarthropathies,
and systemic lupus erythematosus. In this review, we discuss how the epidemiology and pathogenesis of CV events
and OP are overlapping. Smoking, diabetes mellitus, physical inactivity as conventional risk factors as well as systemic
inflammation are among the modifiable risk factors for both CV events and bone loss. In rheumatic patients, systemic
“high-grade” inflammation may be the primary driver of accelerated atherogenesis and bone resorption. In the general
population, in which some individuals might have low-grade systemic inflammation, a holistic approach to
drug treatment and lifestyle modifications may have beneficial effects on the bone as well as the vasculature.
In rheumatic patients with accelerated inflammatory atherosclerosis and bone loss, the rapid and effective
suppression of inflammation in a treat-to-target regime, aiming at clinical remission, is necessary to effectively
control comorbidities.
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Introduction
Multimorbidity may become an increasing challenge in
society [1]. In a study of more than 1.7 million individ-
uals in Scotland, 42% had one or more morbidities and
23% were multimorbid [2].
In the last decades, both cardiovascular (CV) disease
(CVD) and osteoporosis (OP) have been acknowledged
as crucial health problems. Both diseases have a major
impact on daily clinical functioning and quality of life
and most importantly on life expectancy compared with
the general population. Thus, CVD and OP should be
considered major health issues [1–3].
CVD and OP may occur simultaneously in the general
population under non-inflammatory conditions. Both CVD
and OP have also been associated with autoimmune and in-
flammatory rheumatic diseases, such as rheumatoid arth-
ritis (RA), spondyloarthropathies (SpAs), or systemic lupus
erythematosus (SLE) [1, 4–15]. Immuno-inflammatory pro-
cesses may accelerate atherosclerosis and bone loss under
non-inflammatory conditions as well as in inflammatory
rheumatic diseases [4, 16–18]. Immunosuppression in-
cluding targeted therapies aiming at clinical remission
may improve CVD and OP secondary to rheumatic
diseases [4–6, 19].
In this review, we will first briefly discuss the common
pathogenic mechanisms in atherosclerosis and bone loss.
As numerous cells and mediators are implicated in these
processes, we will give only a general overview of these
processes. Then we will discuss the two sides of the
story: clinical and epidemiological evidence of increased
CV risk in OP and bone loss and fragility fractures (FFs)
in patients with CVD. As both CVD and OP are highly
accelerated by systemic inflammation and autoimmunity,
we will briefly present the “Bermuda triangle” of CVD,
OP, and inflammatory rheumatic diseases (Fig. 1). We
will choose RA as a prototype as the greatest amount of
information is available on this disease. Finally, we will
present some evidence that atherosclerosis, OP, and—if
present—inflammation may be simultaneously and ef-
fectively targeted. The aim of this review is to describe
the most relevant common mechanisms between bone
loss and atherosclerosis under both non-inflammatory
and inflammatory conditions. We also wish to put for-
ward the idea of a holistic approach during disease
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prevention and therapy. We want to present a compre-
hensive review that discusses most aspects of this topic.
Therefore, owing to space limitations, not all issues will
be discussed in great detail.
Common mechanisms in the development of
atherosclerosis and bone loss
Conventional risk factors
Atherosclerosis/CVD and OP may share numerous risk
factors (Table 1). Some conventional risk factors are
relevant for both OP FF and CV events. Aging is by far
the most important, but postmenopausal status or estro-
gen deprivation (or both), physical inactivity, and smok-
ing also play major roles [20, 21].
In addition, diabetes mellitus (DM) not only is a
well-known risk factor for CVD [22] but also has a nega-
tive effect on bone strength and increased incidence of
FF, as has been shown recently [23]. There is evidence
that type 1 DM (T1DM) is associated with lower bone
mass, lack of insulin and insulin-like growth factor-1,
and increased levels of pro-inflammatory cytokines lead-
ing to FF. In T2DM, in spite of increased bone mass,
bone strength is decreased because of decreased bone
formation, accumulation of advanced glycation end
products (AGE), and cortical porosity. The paradox of
higher bone mineral density (BMD) with increased FF
risk in T2DM may also be explained by more fre-
quent falls due to, among other things, diabetic
retinopathy and polyneuropathy in addition to the
poorer bone quality [23].
Additional conventional CV risk factors also associ-
ated with increased risk of low BMD may include dyslip-
idemia and hypertension [20]. However, the current
evidence supporting the role of these factors in linking
CVD and OP is not conclusive [20].
Inflammatory risk factors
In addition to traditional risk factors, systemic inflamma-
tion has been implicated in both atherosclerosis and bone
loss. Inflammatory cells, acute phase reactants (for ex-
ample, C-reactive protein, CRP; erythrocyte sedimentation
rate, ESR), several pro-inflammatory cytokines, chemo-
kines, and growth factors and other mediators—including
osteoprotegerin (OPG), receptor activator of nuclear fac-
tor kappa B ligand (RANKL), and sclerostin (SOST)—are
associated with both events [5, 16–18, 21, 24, 25].
“Low-grade inflammation”—including immune cells
(T and B cells, macrophages, and endothelial cells) and
inflammatory mediators—plays an important role in the
pathogenesis of both atherosclerosis and OP. Further-
more, inflammatory rheumatic diseases, such as RA,
SpA, or SLE, have been associated with secondary ath-
erosclerosis, increased CV morbidity and mortality, and
increased bone loss [4, 5, 7, 8, 18, 19, 21]. As described
later, in such “high-grade inflammatory” states, both ath-
erosclerosis and bone loss are even further accelerated,
Fig. 1 The “Bermuda triangle” of atherosclerosis, osteoporosis, and inflammation. Under non-inflammatory states, common conventional risk factors
and “low-grade” inflammation may link atherogenesis and bone loss. In case of an underlying inflammatory disease, such as rheumatoid arthritis,
“high-grade” systemic inflammation may perpetuate the development of atherosclerosis and osteoporosis
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and treatment of the underlying inflammatory disease,
primarily by targeted therapy, may have beneficial effects
on the bone and vasculature [4, 6, 19, 26]. In general,
among inflammatory mediators, CRP, pro-inflammatory
cytokines (for example, tumor necrosis factor alpha
[TNF-α] and interleukin 1 (IL-1), IL-6, IL-17, and
IL-12/IL-23), some chemokines, growth factors, adipo-
kines, and the renin–angiotensin–aldosterone system
are important factors of atherogenesis and bone resorp-
tion [5, 6, 17, 18, 21, 24, 27–29]. For example, elevated
CRP, TNF-α, and IL-6 levels have been associated with
both myocardial infarction (MI) and non-traumatic FF
[21, 29, 30].
Adipokines—primarily adiponectin, leptin, resistin,
and chemerin—have been implicated in atherosclerosis
under both inflammatory and non-inflammatory condi-
tions [31, 32]. Various adipokines may also be involved
in bone remodeling [31, 33]. For example, Varri et al.
[34] performed a study on 290 postmenopausal women
in Finland, in which adiponectin levels were inversely
correlated with total body and femoral neck BMD but
showed no relationship with coronary artery calcifica-
tion (CAC) or carotid artery intima-media thickness
(cIMT). In addition, leptin levels were associated with
CAC [34].
The activated renin–angiotensin system (RAS) pro-
motes atherogenesis. Angiotensin II also activates osteo-
clasts, while angiotensin-converting enzyme inhibitors
may increase BMD and reduce FF risk [24, 35].
Factors primarily involved in bone metabolism
OPG and SOST are known factors related to bone biol-
ogy. However, they have also been associated with CV
events [36, 37]. OPG is a decoy receptor for RANKL
that inhibits osteoclast activation and bone resorption
[37]. In addition, OPG has been implicated in vascular
calcification, matrix rearrangement, diabetic retinopathy,
and most importantly in atherosclerosis, plaque
destabilization, and CVD [36]. RANKL is overexpressed
in vulnerable atherosclerotic plaques and may be able to
reduce the risk of plaque rupture [24]. OPG has been re-
lated to CV morbidity and mortality [24, 38].
SOST is a known inhibitor of Wnt-mediated osteoblast
activation and bone formation. Thus, SOST is involved in
bone resorption and inflammatory bone loss [37, 39].
SOST has been associated with CV mortality in patients
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on hemodialysis [21]. Recently, SOST has been identified
as a possible marker for early atherosclerosis [40].
Bone morphogenetic proteins (BMPs) induce mesen-
chymal cell differentiation toward the osteoblastic
lineage. Various BMPs, primarily BMP-2 and BMP-7,
stimulate collagen synthesis and are involved in bone
formation. BMPs have been implicated in atheroscler-
osis. BMP-2 is expressed by vascular endothelial and
smooth muscle cells. BMP expression is upregulated in
the atherosclerotic plaques. Moreover, vascular BMP-2
expression is regulated by pro-inflammatory stimuli,
such as TNF-α. BMP-4 has been associated with athero-
sclerosis and hypertension [24, 41].
Vitamin D may be considered both traditional and
immuno-inflammatory risk factors for atherosclerosis
with OP. Vitamin D deficiency has been implicated in
bone loss and also in atherosclerosis [42, 43]. With re-
gard to CVD, vitamin D deficiency may indirectly pro-
mote atherosclerosis on the basis of its relationship with
DM, dyslipidemia, and hypertension. However, the exact
mechanisms through which low vitamin D levels may
directly lead from endothelial dysfunction to MI or
stroke are not yet fully understood. Recent studies sug-
gested that pathways potentially targeted by vitamin D
include vascular muscle contractility, inflammatory
mechanisms, oxidative stress, and the uptake of choles-
terol by macrophages [44, 45].
Parathyroid hormone (PTH) is involved in age-related
bone loss. PTH and PTH-related protein may also exert
CV effects. Primary hyperparathyroidism has been asso-
ciated with hypertension as well as increased CV mor-
bidity and mortality [21, 24].
Fibroblast growth factor 23 (FGF-23) regulates phos-
phorous metabolism. Phosphorous may exert direct
toxic effects on the vasculature. FGF-23 and one of its
receptors, klotho, have been implicated in vascular calci-
fication in patients on hemodialysis (see later). In
addition, klotho deficiency and increased FGF-23 may
lead to transformation of endothelial cells into
osteoblast-like cells and mineralization. In contrast, high
klotho expression inhibits vascular calcification [21, 46].
Even in individuals with normal renal function, high
FGF-23 and low klotho levels may be associated with in-
creased CV morbidity and mortality [21, 46] as well as
OP and FF [21, 47].
Osteopontin (OPN) is an extracellular structural pro-
tein stimulated by 1,25-OH-vitamin D3. OPN promotes
bone resorption via several molecular mechanisms. OPN
is an inhibitor of ectopic calcification and vascular calci-
fication [24, 48].
Cathepsin K exerts an important role in osteoclast ac-
tivation and extracellular matrix degradation. Cathepsin
K stimulates the degradation of type I and II collagens
and osteonectin. It induces bone loss. Moreover,
disruption of cathepsin K reduces plaque formation and
the progression of atherosclerosis [24, 49].
Vascular calcification
Vascular medial wall calcification has been associated
mainly with chronic kidney disease (CKD) [50]. The
process involves impaired calcium and phosphate
homeostasis, dysregulated PTH production, and abnor-
mal calcium sensing [50, 51]. Recent studies have evalu-
ated the role of Runx2, RANKL, OPG, and FGF-23 in
CKD-associated vascular calcification [50, 51]. For ex-
ample, as discussed above, high serum FGF-23, high
phosphorous, and low klotho levels have been associated
with increased arterial calcification in patients on
hemodialysis [21]. Arterial calcification in CKD has been
associated with low BMD [52] as well as impaired tra-
becular bone microarchitecture [53].
Surrogate markers indicating a relationship between
atherosclerosis and bone loss
Certainly, the major issue is whether there is epidemio-
logical and clinical evidence for increased CV risk in OP
and increased risk of OP and FF in patients with CVD.
Studies with significant clinical endpoints (MI, stroke,
FF, and even mortality) are necessary to answer these
two questions. It is important to note that in addition to
clinical association studies described later, preliminary
investigations using surrogate markers of subclinical
CVD (for example, cIMT and CAC) were conducted in
order to demonstrate associations with BMD. For ex-
ample, Barengolts et al. [54] assessed coronary calcium
burden by electron-beam computed tomography (CAC)
and lumbar spine BMD in 45 postmenopausal women.
Higher calcium scores were associated with lower BMD
[54]. Campos-Obando et al. [55] assessed BMD and
CAC during a mean of 6.4 years of follow-up in the Rot-
terdam Study. Increased BMD loss was associated with
higher CAC scores in women but not in men. On the
other hand, no associations between CAC and fracture
risk could be observed [55]. Shaffer et al. [56] correlated
cIMT and BMD in 535 women and 335 men. In the sub-
set of individuals older than 60 years, BMD inversely
correlated with cIMT [56]. Finally, Delgado-Frias et al.
[57] found an inverse correlation between OPG levels
and brachial artery flow-mediated vasodilation (FMD), a
marker of endothelial function in patients with RA.
These studies using surrogate markers already suggest
that atherosclerosis/CVD and bone loss/BMD may be
associated.
In conclusion, numerous non-inflammatory (traditional)
and inflammatory factors may link atherosclerosis and
osteoporosis. Some of these factors may be used as surro-
gate markers of the two interrelated processes.
Szekanecz et al. Arthritis Research & Therapy           (2019) 21:15 Page 4 of 10
Increased cardiovascular risk in osteoporosis
As mentioned in the previous section, OP and CVD
have common pathophysiological links and risk factors
[21, 24]. Epidemiological evidence has been found be-
tween an increased risk and prevalence of CVD in pa-
tients with OP [24]. In the recent meta-analysis (of 25
studies with 10,300 patients) performed by Ye et al. [58],
the adjusted incidence of any atherosclerotic vascular
abnormality was significantly increased in individuals
with low BMD versus normal BMD (odds ratio (OR)
2.96) as well as in those with OP versus without OP (OR
2.45) [58]. Veronese et al. [59] performed a meta-ana-
lysis of 11 studies indicating that people with low BMD
are at increased risk of developing CVD during
follow-up with an adjusted hazard ratio (HR) of 1.33
[59]. Moreover, this meta-analysis observed that each de-
crease of BMD by one standard deviation (SD) increased
the CVD risk by 16% (HR 1.16). In regard to specific
CVD types, each BMD decrease by one SD corre-
sponded to a consecutively increased risk of CV and
cerebrovascular disease by 44% and 28%, respectively
[59]. In contrast, Jin et al. [60] published data from the
recent Korean STROBE (Strengthening the Reporting of
Observational studies in Epidemiology) study. They
could not completely confirm the observed association
between cerebrovascular disease and OP, as vertebral or
hip BMD was not associated with cerebral arterial
disease [60].
With respect to associations between FF and CVD,
Veronese et al. [59] reported a significant association be-
tween FF at baseline and subsequent development of
CVD (HR 1.20). FF at baseline was also associated with
an increased risk of cerebrovascular conditions and
death due to CVD [59]. In contrast, in a much earlier
study, Varosy et al. [61] unexpectedly found a decreased
risk of subsequent coronary events in 2700 postmeno-
pausal women with known CVD and skeletal fractures.
In this study, the risk of developing further coronary
events during 4 years’ follow-up was reduced by 25% in
women with FF compared with those without fractures
(HR 0.74). It is important to note that these patients
already had prevalent CVD in addition to FF at baseline
[61]. Therefore, the exact association between FF and
later CVD needs to be determined by conducting larger
prospective studies [62].
Some studies also assessed CV mortality in patients
with OP. In the meta-analysis by Qu et al. [63], an in-
creased risk of CV mortality was described in patients
with OP. A significant relationship between low BMD at
all sites and CV mortality was found. On the other hand,
this study could not demonstrate an association between
cerebrovascular mortality and OP [63]. In a prospective
study of more than 700 individuals, Domiciano et al.
[64] observed increased CVD mortality in patients with
OP as defined by total hip T-score (HR 3.17). Moreover,
this study suggested that a one-SD decrease of total hip
BMD was a predictor for all-cause mortality in elderly
people [64]. These findings are in line with some early
studies that reported increased CV mortality in patients
with OP [21, 24]. However, the recent meta-analysis by
Veronese et al. [59] suggests that publication bias may
have influenced some of the abovementioned results, so
the precise HR of OP on CVD mortality remains to be
elucidated [59].
In conclusion, even in non-inflammatory states and
despite some controversial reports, there is increased
risk of atherosclerosis and CVD in individuals with OP.
Several pathogenic processes may link atherosclerosis to
OP. Moreover, patients with OP should be routinely
screened for atherosclerosis and CVD.
Increased risk of osteoporosis and fragility fractures in
cardiovascular disease
There is evidence suggesting that patients with CVD have
an increased risk of bone loss and FF. Den Uyl et al. [65]
performed a systematic review of seven population cohort
studies on patients with subclinical CVD. Six of the
highest-ranked studies that included a mean of 2000 pa-
tients indicated that subjects with prevalent subclinical
CVD disease had higher risk for increased bone loss and
FF compared with individuals without CVD. This was ob-
served in both women and men. Both vertebral and hip
FFs were observed. The overall HR/OR was 2.3 to 3.0.
The data also suggested that subjects with low BMD
had higher CV mortality rates and incident CV events
than those with normal BMD. In this analysis, the
most important risk factors were age, estrogen defi-
ciency, and inflammation [65].
Sennerby et al. [66] followed almost 32,000 Swedish
twins from the age of 50 years for a mean follow-up time
of 20 years. None of the subjects had CVD at this age.
The main outcome measure was time to hip fracture
after diagnosis of CVD. The crude absolute rates of FF
per 1000 person-years after the diagnosis of heart failure,
stroke, peripheral arterial disease, and ischemic heart
disease compared with no-CVD were 12.6, 12.6, 6.6, and
5.2 versus 1.2, respectively. The adjusted HRs of hip FF
in these CVDs were 4.4, 5.1, 3.2, and 2.3, respectively.
Thus, CVD was significantly associated with subsequent
FF [66].
Gerber et al. [67] followed 3321 patients with incident
MI and 3321 controls until an FF or death occurred.
The overall FF HR in MI patients was 1.32. This HR in-
creased according to time period: in 1979–1989, 1990–
1999, and 2000–2006, the HRs were 0.81, 1.47, and 1.73,
respectively [67]. These changes could be explained by
increasing age over time as well as other environmental
factors.
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Finally, Pouwels et al. [68] assessed the risk of hip/
femur FF after stroke. The adjusted ORs of FF in any
stroke and hemorrhagic, ischemic or undefined stroke
were 1.96, 1.94, 1.85, and 2.10, respectively, compared
with those subjects who never experienced stroke [68].
In conclusion, there is increased risk of bone loss, OP,
and FF in patients with CVD. A number of mechanisms
may lead to bone loss in CVD. Furthermore, patients
with CVD should be regularly screened for OP.
Cardiovascular disease and osteoporosis in inflammatory
rheumatic diseases
Patients with inflammatory rheumatic diseases not only
may suffer from their disease but also may have comor-
bidities [1, 13]. The greatest amount of information has
become available in RA [1, 4, 13]; therefore, we will
mostly discuss this disease with implications for other
inflammatory rheumatic diseases. For example, in the
large COMORA (Comorbidities in Rheumatoid Arth-
ritis) study of 4586 patients with RA in 17 countries, a
high prevalence of comorbidities and their risk factors
was found, but the variability between countries in the
prevalence and also in the detection of comorbidities
was highly variable [13]. In a recent prospective Swedish
cohort of 950 patients with early RA, factors associated
with the development of one or more comorbidities, in-
cluding CVD, stroke, and OP, were analyzed. Disease ac-
tivity and ESR were among the most common risk
factors for comorbidities, indicating the importance of
inflammation [25].
As already mentioned above, both CVD and OP have
been associated with RA as well as other types of arth-
ritis (for example, SpA) and autoimmune connective tis-
sue diseases (for example, SLE) [1, 4–15, 69]. The risks
of both CVD and FF are increased, roughly doubled in
RA, carrying a large impact on the quality of life in these
patients [4, 8, 13, 15, 69]. Again, the crucial question is
whether these comorbidities, as described above, are also
interrelated under inflammatory conditions. Relatively
few studies have been carried out in RA or SLE assessing
whether a fracture would be a risk factor for a CV event
or CVD would increase OP or FF risk.
With respect to CVD and OP in arthritis and auto-
immune patients, a recent population-based cohort
study by Ni Mhuircheartaigh et al. [70] indicated a sub-
stantial increase of CVD development in RA patients
with FF. In this study, 1171 incident RA patients com-
pared with 1171 non-RA subjects with a sustained FF
were followed for 12 years for further CVD development.
In controls, FF was not associated with increased CV
risk (HR 1.10–1.12). However, in RA subjects with FF,
significantly increased CV risk was shown (HR 1.81 for
FF and 1.80 for major OP fracture subjects) [70]. To the
best of our knowledge, no other studies on FF and CVD
development in rheumatic conditions have been
performed.
With respect to non-FF studies, Popescu et al. [71] re-
ported that patients with RA and CV comorbidity had
lower total bone mass. Provan et al. [72] presented
15-year follow-up data from the Oslo RA Register. RA
patients, who deceased from primary atherosclerotic
death including both CV or cerebrovascular disease,
were more often suffering from OP (57% versus 36%)
and previous fractures (38% versus 21%) compared with
those who did not die of CVD [72].
In other rheumatic diseases, such as SLE, the informa-
tion on CV risk in OP is limited. The only studies pub-
lished used surrogate markers for CVD, such as carotid
ultrasound rather than clinical CVD data. Ramsey-Gold-
man and Manzi [14] reported associations between more
carotid plaques or coronary calcification and low BMD
in young patients with SLE.
Autoantibodies play a major role in the pathogenesis of
RA and other autoimmune diseases. Anti-citrullinated
protein antibodies (ACPAs) and rheumatoid factor (RF),
which play an essential role in RA, may also be associated
with atherogenesis and bone loss. Indeed, both ACPA and
RF positivity have been associated with increased CV risk
in RA [73]. Furthermore, ACPA and RF, even independ-
ently of inflammation, may synergistically induce bone re-
sorption in RA [74].
In conclusion, inflammatory processes and underlying
inflammatory diseases may enhance the development of
both atherosclerosis and OP. “Accelerated” or “inflam-
matory” atherosclerosis and bone loss have been associ-
ated with RA and other inflammatory conditions.
Therefore, such patients should be routinely screened
for CVD and OP.
Possibilities of parallel targeting of cardiovascular disease
and osteoporosis
Although some anti-OP drugs may have favorable CV
effects and inversely some vasoactive agents may have
positive effects on the bone, it is more likely that in the
case of arthritides and autoimmune diseases, treatment
of the underlying disease may also improve CV and OP
comorbidities [4, 6, 19]. There have been multiple stud-
ies in this field, so here we only briefly summarize gen-
eral considerations.
Vitamin D has been considered an essential back-
ground treatment and preventative compound in OP.
Vitamin D deficiency has also been associated with
T1DM and CVD [42, 45]. Furthermore, vitamin D exerts
numerous immunomodulatory properties and thus may
be used in immuno-inflammatory diseases [42, 45].
Calcium supplementation has been implicated in the
development of CVD in the general population, but this
issue is still under debate. This association was
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suggested by some large studies (for example,
NIH-AARP) but conflicted by others (for example, Fra-
mingham and the Women’s Health Initiative) [72, 75].
Interestingly, according to a recent study, calcium sup-
plementation together with high (but not with low) ESR
was associated with increased all-cause and CV mortal-
ity of patients with RA [72]. However, it is difficult to
evaluate calcium supplementation as a CV risk in RA. It
is possible that calcium was mostly prescribed to RA pa-
tients with OP who already have a high background risk
for CVD.
Among anti-OP agents, bisphosphonates in some studies
inhibited atherogenesis and significantly decreased serum
low-density lipoprotein (LDL) and increased high-density
lipoprotein (HDL) in postmenopausal women [20]. Yet the
effect of bisphosphonates on CV risk is not clear, but a re-
duction in mortality was prescribed for zoledronic acid after
a hip fracture [76]. As described above, OPG has been
linked to vascular calcification and CVD [36]. Therefore, it
is an important question whether RANKL inhibition by
denosumab would affect the CV system. Samelson et al.
[77] compared more than 2300 denosumab- or placebo-
treated patients from the FREEDOM (Fracture Reduction
Evaluation of Denosumab in Osteoporosis every 6 Months)
trial. RANKL inhibition had no effect at all on the progres-
sion of arterial calcification or on the incidence of CV
events [77].
On the other hand, statins and nitrates, agents used in
vasculoprotection, may also have beneficial effects on
the bone [20, 78]. Weaker evidence suggests that thia-
zide diuretics and β-blockers may also exert favorable ef-
fects on bone [78]. By contrast, some drugs, such as
loop-acting diuretics and warfarin, may aggravate bone
loss [78]. There have been very few prospective trials in
this respect, so the effects of heart drugs on bone should
be confirmed by future studies [78].
With respect to anti-rheumatic and anti-inflammatory
drugs used to treat RA and other inflammatory rheum-
atic diseases, there has been a lot of controversy on the
benefits versus risks of low-dose corticosteroid treat-
ment. In general, corticosteroids indeed may be
pro-atherogenic [79] and may stimulate bone loss [80].
However, in RA, the anti-inflammatory effects of
low-dose corticosteroid treatment may be beneficial for
vasculature and bone. The net effect of corticosteroids
on CVD and OP may vary in different diseases and pa-
tients [4, 5, 26, 79–82]. According to a recent OP con-
sensus paper by the ESCEO (European Society for
Clinical and Economic Aspects of Osteoporosis and
Osteoarthritis) [81] and the recent EULAR CV recom-
mendations [4], short durations and moderate doses of
glucocorticoids are recommended. In this case, cortico-
steroids are generally well tolerated and have a positive
benefit/risk ratio. Yet patients on corticosteroid therapy
should be regularly assessed for CV and FF risk and, if
needed, should be treated [4, 80, 81].
Among conventional synthetic disease-modifying anti-
rheumatic drugs (csDMARDs), methotrexate (MTX) may
exert beneficial effects on bone and on the CV system pri-
marily by controlling systemic inflammation [4, 5, 26, 82].
MTX has not only indirect but also direct effects on bone
resorption [83] and lipid metabolism [5].
In brief, biologic DMARDs (bDMARD), primarily
TNF inhibitors, may also decrease inflammatory athero-
genesis [5, 17, 19, 84], may lower the risk of CVD [4, 5,
19, 82, 85, 86], and may halt periarticular and general-
ized bone loss [6, 26, 87, 88] in inflammatory rheumatic
diseases. Moreover, according to a recent study, RA pa-
tients receiving TNF inhibitors had even lower risk of
MI compared with those treated with csDMARDs [86].
In a recent prospective early RA cohort, the use of bio-
logics was inversely associated with the risk of comor-
bidity development [25].
Finally, in addition to the EULAR recommendations on
CVD management in rheumatic diseases [4] and the
recent EULAR/European Federation of National Associa-
tions of Orthopaedics and Traumatology (EULAR/
EFORT) recommendations on the management of FF [9],
a EULAR initiative published “points to consider” for
reporting, screening, and preventing comorbidities in pa-
tients with chronic inflammatory rheumatic diseases. This
paper focuses on six comorbidities, including CVD and
OP. These recommendations also include advice on life-
style modifications in addition to drug therapy [89].
In conclusion, one can set up a holistic approach to
the management of CVD and OP, especially in patients
with inflammatory rheumatic diseases. The understand-
ing of common pathogenic factors, as molecular targets,
may help us to design novel strategies that combat both
CV disease and bone loss.
Conclusions
In an aging population, comorbidities such as CVD or OP
occur more frequently. These comorbidities develop even
more often in patients with inflammatory rheumatic dis-
eases such as RA and SLE. These interactions are plotted
in Fig. 1 as a “Bermuda triangle”. Although rheumatolo-
gists nowadays are successful in treating their patients ac-
cording to the treat-to-target design (particularly in RA),
it is obvious that this single disease framework may not
cover all comorbidities; therefore, comorbidities are still
suboptimally prevented, screened, and managed. In this
review, we discussed how the epidemiology and pathogen-
esis of CV events and OP are strikingly overlapping.
Theoretically, smoking, DM, and sedentary lifestyle as
conventional risk factors and systemic inflammation are
among the modifiable risk factors for both atherosclerosis
and bone loss. A holistic approach to treatment may
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involve the use of drugs and lifestyle modifications that
may have beneficial effects on bone as well as on vascula-
ture. In RA patients with accelerated inflammatory
atherosclerosis and bone loss, the rapid and effective sup-
pression of inflammation by corticosteroids, csDMARDs,
and bDMARDs in a treat-to-target manner aiming at
clinical remission is necessary to effectively control
comorbidities.
One of the limitations of the reviewed dataset is that
most of the studies have been conducted in Caucasian
women; thus, extrapolation to men and women of differ-
ent genetic background is not possible. Another issue is
that the associations of CVD and OP in patients with
RA are highly dependent on the underlying systemic in-
flammation. Thus, it is not clear whether a similar rela-
tionship would be valid in modern times, when RA
therapy is aiming at clinical remission. Finally, possibly
the most important limitation is that almost no data
have been presented on the relationship between cumu-
lative disease activity, functional capacity and/or radio-
logical damage and the risk of CV events and/or OP in
patients with arthritis. For example, in the recent study
by Ni Mhuircheartaigh et al. [70] discussed above, the
risk of a CV event is 80% higher in RA patients after a
fracture but is likely to be even higher in RA patients
with high disease activity and lower in patients in clinical
remission. Thus, there is still a lot of work to do both in
research and in daily practice: the conduction of more
prospective studies that assess the epidemiological, clin-
ical, and pathophysiological characteristics of CVD and
OP in parallel is urgently needed, but optimal treatment
aiming at remission and advocating lifestyle factors in all
our patients is also a challenge.
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